Centiva Capital, LP Alnylam Pharmaceuticals, Inc. Call Options Transaction History

Centiva Capital, LP

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$233.81 - $287.01 $116,905 - $143,505	500 Added 50.0%	1,500 $412,000
Q2 2024 Aug 14, 2024	BUY	$143.31 - $247.0 $143,310 - $247,000	1,000 New	1,000 $243,000
Q3 2023 Nov 14, 2023	BUY	$170.77 - $211.65 $426,925 - $529,125	2,500 New	2,500 $442,000
Q2 2022 Aug 17, 2022	BUY	$120.42 - $169.29 $445,554 - $626,373	3,700 Added 284.62%	5,000 $729,000
Q1 2020 May 15, 2020	SELL	$93.12 - $133.99 $102,432 - $147,389	-1,100 Reduced 45.83%	1,300 $141,000
Q3 2019 Nov 13, 2019	BUY	$70.9 - $87.82 $170,160 - $210,767	2,400 New	2,400 $193,000

650

109M

1.28M

1.23M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $33.4B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Centiva Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Centiva Capital, LP with notifications on news.